RCT-2100

N/A

Report date: 2025/11/18 14:57:42

Base Information

Drug NameRCT-2100
Drug Alias NameRCT2100RCT-2100
ClassificationCell and gene therapy > Gene therapy > mRNACell and gene therapy > Gene therapy > LNP
Mechanisms of ActionCystic fibrosis transmembrane conductance regulator stimulants
TargetsCystic fibrosis transmembrane conductance regulator
Therapy Area/IndicationsCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsNew Zealand +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRecode Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesRecode Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCystic Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A